Loading company…
RabPharma researches peptide-drug conjugates and treatments for bone and joint diseases.
RabPharma develops drug candidates and a platform for peptide-drug conjugate coupling and screening. Its osteonecrosis treatment RAB001 completed a Phase I trial in the U.S. and received clinical approval in China. Founded in Zhongshan in 2021, it closed a Series A++ round in September 2025 led by Baheal Pharmaceutical Group.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in